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Larger keratinocyte carcinoma (KC) lesions are associated with higher morbidity. This study examined the as-
sociation of potentially modifiable characteristics, including treatment delay, with KC defect size after Mohs' mi-
crographic surgery (MMS). A stratified random sample of patients treated for KC with MMS were selected for
telephone interview. Two hundred and nineteen interviews were completed (refusal rate 24%). Regression models
were used to examine the predictors to defect size and delay. Anatomic site, age, histology, and gender predicted
defect size (R2 = 0.39) and were used as control variables. Self-reported delay between initial physician examination
and MMS predicted defect size (p = 0.0004), with greater than 1 y delay being associated with a doubling of defect
size (adjusted odds ratio (OR) 2.0; 95% confidence interval (CI) 1.3-3.1). Delays of this duration were associated
with initial examination by a primary provider (unadjusted OR 3.9; 95% CI 1.7-8.8), misdiagnosis (unadjusted OR
6.8; 95% CI 2.5-18.7), being treated without biopsy (unadjusted OR 23.3; 95% CI 6.5-83.7), and multiple surgical
removals (unadjusted OR 6.2; 95% CI 2.5-15.5). All but provider specialty were independent predictors of delay.
Attention to processes of care delivery for KC may have a greater impact on morbidity than efforts are earlier
detection by the public.
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Skin cancer is the most common cancer in the United
States. The American Cancer Society estimates that more
than one million cases of keratinocyte carcinoma (KC) (We-
instock et aI, 2001), which includes basal cell carcinoma
(BCC) and squamous cell carcinoma (SCC), are diagnosed
each year (Jemal et aI, 2003). Mortality from KC is relatively
low. They, however, usually arise in cosmetically sensitive
areas, such as the face, and advanced lesions are associ-
ated with higher morbidity and more frequent recurrence
(Miller, 1991; Smeets et aI, 2004). The potentially modifiable
factors that contribute to more advanced lesions at the di-
agnosis of the KC have not been established.
Skin cancer information campaigns and screening pro-
grams are based on the presumption that earlier disease
diagnosis can minimize disease impact (Silfen et aI, 2002).
In the last several decades there have been some investi-
gations of the association of delay, either by patient or
provider, and the extent of tumor invasion, with the over-
whelming majority of these studies focusing on melanoma
(Levine et aI, 1981; Temoshok et aI, 1984, 1985; Cassilet,h
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval;
KC, keratinocyte carcinoma; MMS, Mohs micrographic surgery;
OR, odds ratio; SCC, squamous cell carcinoma
et aI, 1988; Rampen et aI, 1989; Dunkley and Morris, 1991;
Hennrikus et aI, 1991; Blum et aI, 1999; Oliveria et aI, 1999;
Richard et aI, 1999, 2000a, b; Brochez et aI, 2001; Osborne
and Hutchinson, 2001; McKenna et aI, 2002; Schmid-
Wendtner et aI, 2002; Silfen et aI, 2002). The data regarding
the relationship of treatment or diagnostic delay with KC
size is very limited (Kirkup and De Berker, 1999).
We sought to determine the association of.. potentially
modifiable characteristics, including delay in treatment, with
size of defect at the time of KC removal by Mohs lilicro-
graphic surgery (MMS). MMS is accepted as the most ef-
fective KC treatment modality for high-risk cancers because
of its cure rate of approximately 97%-99% (Rowe et aI,
1989; Randle, 1996). Because the technique involves care-
ful histological examination of tumor margins, Mohs surgical
defect size approximates tumor size (Zitelli et aI, 1997).
Therefore, we have chosen the final defect size prior to re-
pair to be a proxy for KC size in our study. We hypothesized
that patients with longer delay would have larger defects.
Results
No differences were found between interviewed and non-
interviewed subjects regarding defect size (mean size: 4.3
Copyright © 2004 by The Society for Investigative Dermatology, Inc.
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Table I. Comparison of interviewed and non-interviewed
subjects n =500 (%)
Females 94 (42.9) 110 (39.1) 204 (40.8)
Males 125 (57.1) 171 (60.9) 296 (59.2)
Total subjects 219 281 500
<40 8 (4) 3 (1) 11 (2)
41-50 29 (13) 15 (5) 44 (9)
51-60 36 (16) 47 (17) 83 (17)
61-70 43 (20) 36 (13) 79 (16)
71-80 80 (37) 87 (31) 167 (33)
81-90 22 (10) 83 (30) 105 (21)
>90 1 (O) 10 (4) 11 (2)
Morpheaform BCC 10 (4.6) 13 (4.6) 23 (4.6)
Infiltrating BCC 22 (10.0) 27 (9.6) 49 (9.8)
Superficial BCC 6 (2.7) 6 (2.1) 12 (2.4)
B\3.sosquamous BCC 4 (1.8) 10 (3.6) 14 (2.8)
Nodular BCC 60 (27.4) 77 (27.4) 137 (27.4)
SCC in situ 13 (5.9) 17 (6.0) 30 (6.0)
Moderately differentiated SCC 5 (2.3) 6 (2.1) 11 (2.2)
Well-differentiated SCC 18 (8.2) 16 (5.7) 34 (6.8)
Superficial SCC 4 (1.8) 5 (1.8) 9 (1.8)
Other types of SCC 8 (3.7) 8 (2.8) 16 (3.2)
No histological 69 (31.5) 96 (34.1) 165 (33.0)
subtype available
Total
(%)
Non-
interviewed
(%)
Interviewed
participants
(%)
aL9gistic regression Wald X2 = 15.46, P= 0.7.
bLogistic regression Wald x2 = 28.55, P< 0.0001.
CLogistic regression Wald X2 = 3.149, P= 1.0.
d X2=0.726, p=O.4. lBee, basal cell carcinoma; sec, squamous 'cell carcinoma.
Upper limb 4 (1.8) 1 (0.4) 5 (1.0)
Back 1 (0.5) 1 (0.4) 2 (0.4)
Chest 3 (1.4) 2 (0.7) 5 (1.0)
Posterior ear 2 (0.9) 5 (1.8) 7 (1.4)
Anterior ear 18 (8.2) 27 (9.6) 45 (9.0)
Eye 17 (7.8) 23 (8.2) 40 (8.0)
Neck 6 (2.7) 5 (1.8) 11 (2.2)
Submandible 1 (0.5) 0(-) 1 (0.2)
Jawline 1 (0.5) 2 (0.7) 3 (0.6)
Chin 5 (2.3) 3 (1.1) 8 (1.6)
Vermillion lip 6 (2.7) 5 (1.8) 11 (2.2)
Anterior lip 7 (3.2) 11 (3.9) 18 (3.6)
Alar lip 5 (2.3) 14 (5.0) 19 (3.8)
Nose 39 (17.8) 66 (23.5) 105 (21.0)
Nasofacial fold 20 (9.1) 17 (6.1) 37 (7.4)
Cheek 26 (11.9) 31 (11.0) 57 (11.4)
Pre-auricular 4 (1.8) 6 (2.1) 10 (2.0)
Post-auricular 3 (1.4) 3 (1.1) 6 (1.2)
Forehead 26 (11.9) 20 (7.1) 46 (9.2)
Scalp 25 (11.4) 39 (13.9) 64 (12.8)
Anatomic sitea
Age (y)b
Histologic subtypeC
Gendert
vs 4.4 cm2 , T test = 0.16, P= 0.9), anatomic location, his-
tologic subtype, or gender (Table I). Interviewed participants
were younger (mean age: 66 vs 72 y, T test = 5.64,
P< 0.0001) than those not interviewed.
In the overall study population (Table II), a substantial
portion of the variation in defect size was explained by his-
tology, age, gender, and anatomic location (R2 = 0.39,
p<0.0001). No age by gender interaction was identified,
and the quadratic age term was not assoCiated with defect
size. The majority of the variance was attributed to anatomic
location (partial R2 = 0.29). Larger surgical defects were as-
sociated with several anatomic sites, including pre- and
post-auricular, chest, and the submandible. There was no
association when BCC was compared with SCC (~ = -0.16,
95% confidence interval (CI) -0.4 to 0.04, P= 0.12). When
more refined histologic subtype was entered into the model,
superficial, morpheaform, and infiltrating BCC were asso-
ciated with larger defects as were older age and male gen-
der. Similar findings were also observed in the analysis of
interviewed participants (R2 = 0.47, anatomic site partial
R2 = 0.37).
Controlling for anatomic location, histology, age and
gender, all time-delay intervals were associated with defect
size when examined individually (p-values from partial F
test: discovery (p = 0.034, median = 194 d), suspicion
(p = 0.014, median = 138 d), initial evaluation (p = 0.004,
median = 107 d), and biopsy (p = 0.025, median = 90 d)).
When an additional time-delay interval was, however, en-
tered into a model already containing one of the time-delay
intervals, significance for both time-delay intervals was lost,
with one exception. Consistently, only delay from initial
evaluation (the duration of time between initial provider
evaluation until MMS) was associated with larger defects
(partial R2 = 0.018, P= 0.004) whereas all other time-delay
intervals failed to maintain a significant association with
size. We evaluated the duration-response relationship be-
tween delay from initial evaluation and defect size (Table III).
The size-delay association was seen only in the last quintile
of time delay, Le. greater than 1 year, which was associated
with a doubling of defect size (size ratio (el)) = 2.0; 95% CI
1.3-3.1).
Controlling for anatomic location, gender, age, and his-
tologic subtype as well as with or without delay (Table IV),
other factors were then examined to further explain variation
in defect size. Size variation was not explained by personal
or family history of skin cancer or by specialty of initial care
provider. No variation was attributable to marital status,
education level, smoking, provider skin examination, per-
sonal history of previous cancer other than skin, number of
provider visits in the 2 years prior to surgery, treatment by
initial health provider, if skin cancer was diagnosed initially,
the Whitley index, the attitudinal variables, medical costs, or
insurance concerns.
Defect size (p-value based on partial F value) was asso-
ciated with who discovered lesion (self, spouse, or a clini-
cian; p = 0.014), skin Belf-examination (SSE) (p = 0.035)", and
the number of prior removals (p = 0.03). All of these factors,
however, failed to maintain the significance in controlling
for anatomic location, histologic subtype, age, gender,
and time interval greater than 1 years between' provider
evaluation and surgery. Out-of-pocket cost of diagnosis
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had a marginal association with larger lesions (~= 0.005,
p=0.049).
In separate logistic regression analyses, we examined
factors associated with long delay (dependent variable:
greater than 1 yfrom evaluation until MMS). The initial pro-
vider seen was a dermatologist for 68% of patients whereas
most of the remaining patients saw a primary provider first
(Table V). Patient who saw a primary care provider first,
compared with those who saw a dermatologist, were more
likely to'have a long delay (unadjusted odds ratio (OR) 3.9;
95% GI 1.7-8.8). Delay was not associated with reason for
initial office visit. The provider's initial diagnostic impression
of the lesion at the time of initial evaluation, however, dif-
fered in those with more than a year delay compared with
those with shorter delay. If the skin cancer was· misdiag-
nosed initially (unadjusted OR 6.8; 95% GI2.5-18.7) or if the
lesion was treated as opposed to biopsied on the initial
evaluation (unadjusted OR 23.3; 95% GI 6.5-83.7), the pa-
Table II. Predictors of log-surgical defect size (weighted
multiple linear regression, N = 500)
Variable Partial R2 DF F p-value
Anatomic site 0.29 19,480 10.1 <0.0001
Age (y) 0.044 1479 31.6 <0.0001
Histologic subtype 0.045 10,469 3.39 0.0003
Gender (female = 1) 0.016 1468 11.9 0.0006
Overall model 0.39 31,468 10.4 <0.0001
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tient was more likely to have delay. Patients who had one
(unadjusted OR 6.2; 95% GI 2.5-15.5) or more prior sur-
geries (unadjusted OR 47.3; 95% GI 5.5-403.8) before MMS
were also more likely to have a long delay. Using multivari-
ate logistic regression, delay of more than 1 y from initial
evaluation until MMS was associated with initial misdiag-
nosis, initial treatment, and having one or more removals
prior to MMS (Table V). No other variables, including an-
atomic location, histologic subtype, age, and gender were
significantly associated with delay.
Discussion
This study suggests that there are several facfors that are
associated with the size of MMS defects in the treatment of
KG. Delay of more than 1 y between initial provider eval-
uation of a KG and its surgical removal with MMS was as-
sociated with surgical defects that were twice as la'rge as
those where delay was shorter. We note that important
predictors of th,is delay include initial misdiagnosis, initial
procedure performed, and the number of surgical remmJals
prior to MMS. We also found important effects of anatomic
site, age, histologic subtype, and gender on defect size,
with the largest portion of the variation in size explained by
anatomic site. This is consistent with previous findings in
which both anatomic location and histologic subtype have
been noted to be associated with the extent of infiltration
and tissue invasion in KG (Batra and Kelley, 2002). In our
Table III. Association of defect size with delay from initial evaluation
Duration of delay Number of
from initial evaluation subjects Coefficient P(SE) Size ratio (CI)a p-value
<1 mo 41 0 1 \ (Reference)
1-3 mo 35 -0.06 (0.22) 0.9 (0.6-1.4) 0.8
3-6 mo 41 -0.10 (0.21) 0.9 (0.6-1.4) 0.6
6-12 mo 39 0.06 (0.20) 1.1 (0.7-1.6) 0.8
More than 1 y 40 0.70 (0.22) 2.0 (1.3-3.1) 0.0016
Unknown 23
Coefficients are standardized with anatomic site, age, histologic subtype, and gender controlled in analysis. The dependent variable was the log of
defect size (cm2). p-value is based on F test. ,
aSize ratio is defined by using e13 , e.g. eO.70 = 2.0, which clinically represents a doubling of defect size.
CI, confidence interval. '
Table IV. Predictors of defect size in interviewed sample (n = 219)
Variable Coefficient (P) DF SE Partial R2 p-value
Anatomic site - 19,199 - 0.37 <0.0001
Age (y) 0.01 1198 0.005 0.019 0.014
Histologic subtype - 10,188 - 0.044 0.16
Gender (female = 1) -0.33 1187 0.15 0.027 0.0039
Delay> 1 y from initial exam until MMS 0.73 1186 0.17 0.054 <0.0001
Final model 32,186 0.52 <0.0001
MMS, Mohs micrographic surgery.
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Table V. Health system factors that predict delay from initial evaluation until MMS (n = 196)
Delay> 1 Y (%)
Specialty of first provider to evaluate lesion
Less delay (%) Univariate OR (95% CI) MUltivariate OR (95% CI)a
\
Dermatologist 19 (48) 115 (73) 1.0 -
Primary care provider 14 (35) 1 22 (14) 3.9 (1.7-8.8) -
Other/unknown 7 (~7.p) 19 (12.2) 2.2 (0.8-6.0) -
Initial diagnosis of first evaluating provider
Skin cancer 10 (25) 79 (51) 1.0 1.0
Other benign lesion 12 (90) 14 (9) 6.8 (2.5-18.7) 3.2 (1.2-8.5)
Other/unknown '- 18 (45) 63 (40.4) - 2.3 (1.0-'-5.2) 1.3 (0.5-3.2)
Procedure performed by first evaluating provider
'.'
Biopsy 13'(32.5) 109 (70) 1.0 1.0
Treated 11 (27.5) 4 (3) 23:3 (6.5-83.7) 9.3 (2.2-38.4)
No procedure 15 (37.5) 43 (27.6) 3.~ (1.4-7.3) 2.8 (1.1-6.9)
Other/unknown 1 (2.5) - .,
Number of lesion removals prior to MMS
\
21 (52.5) 142 (91)0 1.0 1.0
1 12 (30) 13 (8.3) 6.2 (2.5-15.5) 4.1 (1.3-12.6)
>1 7 (17.5) 1 (1) 47.3 (5.5-403.8) 42.4 (4.5-395.8)
.' ,
aMultivariate model with initial diagnosis of first evaluating provider, pro,cedure performed by first provider, and number of lesion removals prior to
MMS inclUded. )
MMS, Mohs micrographic surgery; OB, odds ratio; CI, confidence interval.
, n
study, a woman's surgical defect size was approximately'
half the size of a man's defect.
There are several limitations of our study. One limitation
is the absence of data from referring providers and the un-
certainty of detailed explanations for the long delays (great-
er than 1 y) between initial evaluation and MMS. We do not
have detailed information on prior medical oare, including
prior treatment with electrodessication and curettage, a rel-
atively common treatment method for KC (Silverman et aI,
1991). This study did not examine adequacy of pathology
specimens (Rampen et aI, 1989) or result follow-up (Gassi-
leth et aI, 1988). We do not know if there were difficulties
surrounding the reason for the referral of suspected skin
lesions (Dunkley and Morris, 1991) or misunderstandings of.
the urgency of scheduling the referral evaluations (Dunkley
and Morris, 1991; Brochez et aI, 2001). Furthermore, most
of our data was collected by self-report, including the in-
formation relating to dates and progression through the
medical system prior to MMS. Imprecision in the assess-
ment of delay is possible because of inaccurate or non-
specific recall of dates. To minimize potential err,or intro-
duced by recall bias, the time intervals used the date of
MMS, a date available in the medical record.
Another limitation of this study is that some pathology
reports were incomplete or missing. Histologic-subtype
identification and verification 'were not available for all
tumors. Ideally this information would have been present for
all individuals. Furthermore, we have noted an association
with diagnostic suspicion' of lesion on first evaluation, initial
care plan and number of prior surgical removals with delay.
There may, however, be other sources of delay that we did
'not adeq'L~ately 'assess, iRcluding severe unrelated illness
in the interval between initial evaluation and MMS, patient's
persbnal priorities, problems with referring or schedUling
appointlilents, or additional visits related to "following"/ob-
serving lesion. '
A'strength of this study is that it examines factors as-
sociated with defect size itself, a measure of KC morbidity.
The use of surgicalcdefect margins from MMS cases allows
a precise estimat~ of tumor size. This study demonstrates
evidence of the association, Qetween treatment delay and
KG outcomes. All 'cases werj3 obtained from the practice of '
a single Mohs surgeonl At the time of this study, a majority
of all MMS cases in the state of Rhode'lsland were treated
by this dermatologic surgeon. The use of a single surgical
provider reduces proVider-associated variability and cases
are felt to be representative of Rhode Island KG patients. It
is unclear if these results are generalizable outside of this
population, including patients not referred for Mohs surgery.
A review of patient care delay for cancer symptoms
shows that cancer patients with co-paid fee-far-service
coverage waited longer to seek healthcare than patients
enrolled in health maintenance organizations (Love, 1991).
Although almost all study participants had medical cover-
age, co-payments and fear of non-covered expenses could
conceivably have contributed to patient delay in this study
population. Participants were, however, asked specifically if
the cost of seeing a health provider was a barrier to care,
and we found no significant association betwe'en response
to this question and defect size. The meaning of the ob-
served borderline association found bet~een out of pocket
expense and surgical defect size is unclear.
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There has been limited investigation of the relevance of
treatment delay and KC size (Kirkup and De Berker, 1999;
Bandaranayake, 2002). Kirkup and De Berker (1999) exam-
ined 50 patients with BCC on the- face who were identified
as suitable for elective excision. Major and minor diameters
(Le. horizontal and vertical dimE?nsions of lesion) were
measured at presentation and immediately before excision.
Delay time ranged from 3 wk to 6' mo (mean of 10 wk), and
60 correlation was found with ';'change in size and time to
surgery. The authors did note, that because of the poor
correlation between growth and ti~e, that it was difficult to
predict the effect of longer delays. FUl1:hermore, it should be
noted that if our study had used the same delay period of
6 mo or less, we too would have found no assqciation
between delay and size. '
A recent doctoral dissertation examined the relationship
of delay to KC size (Bandaranayake, 2002). Althoug~ this
Australian case-control study included people with smaller
lesions and shorter duration of delay, her results were con""' ,
sistent with our findings. Bandaranayake noted longer delay
between the final physician evaluation and definitive treat-
ment in those with largerlesions (cases: greater than 1-2.25
cm2). Controlling for sex, age, and histology, patients with
longer delay (more than 61 d) between consultation with .
final physician until definitive treatment were more likely to
have larger lesions than those treated within 2 wk (OR 1.96;
95% CI 1.42-2.71). She, however, found evidence that the
delay was attributable to the more complex procedures re-
quired for treatment of the larger lesions.
Patient and tumor factors that relate to subclinical ex-
tension of non-melanoma skin cancer were examined in a
study of 1131 MMS patients using a dependent variable of 3
or more MMS layers during surgery. The authors noted an
interaction between anatomic location of the skin cancer,
histologic classification, and sex that was predictive of the
extent of subclinical invasion. Tumors located on the eye-
lids, temple, or ear helix; basosquamous, morpheaform,
nodular, and recurrent BCC on the nose; and morpheaform
BCC on the cheek were found to be important predictors of
extension. Pre-operative size greater than 10 mm and re-
current malignancies or those on the neck in men also were
predictive of infiltration (Batrarand Kelley, 2002). Although
our study differed substantially in methods, the results were
broadly consistent.
Previous studies have focused on the examination of
factors contributing to health-care delay and thickness of
melanoma. The association between delay and size has
been inconsistent (Cassileth et aI, 1988; Krige et aI, 1991;
Schmid-Wendtner et aI, 2002). Temoshok et al (1985) found
that the most significant variable in a hierarchical multiple
regression analysis of melanoma thickness was delay
(p < 0.0005), defined as time from patient first becoming
suspicious of lesion until evaluation by a physician specif-
ically for that reason. Other than skin type, no significance
was found for other variables including previous knowledge,
understanding of treatment, age, faith, and personality.
Richard et al (1999, 2000a, b) investigated delay and
melanoma thickness using five dates, similar to those used
in this study: when the lesion was first noticed, first suspi-
cion of lesion, first examination by a provider, first proposed
removal, and melanoma resection. Her findings, suggested
,-
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that in some groups, patient and provider delay may be
associated with melanoma depth (Richard et aI, 1999), al-
though the relationships, when present, were complex.
Some prior studies examining melanoma thickness have
found an association between initial examining physician
specialty and melanoma thickness (Richard et aI, 2000a, b)
whereas others have failed to find an association (Brochez
et aI, 2001). In our data, it does not appear that the specialty
of the initial provider (primary care provider or a dermatol-
ogist) was associated with size' or delay, after controlling for
other factors. We also did not find the number of prior sur-
gical removals to be associated with the lesion size. This is
consistent with a study by Brochez et al (2001) that found no
association of prior treatment with melanoma thickness.
Unlike Brochez, we, however, found an association with
prior removals and 'delay.
We were able to explore the relationship between diag-
nostic and treatment delay and KC size in greater depth
" than other studies. Although the results from this study do
n,ot prove that delay causes larger surgical defects, it does
sLlggest an important association. Besides the number of
prior removals, we note several aspects of the initial pro-
vider evaluation that relate to this delay, including the initial
diagnostic impression and type of procedures performed at
this evaluation. Some have speculated about the role of
medical providers in prolonged delay (Cassileth et' aI, 1988;
Dunkley and Morris, 1991; Blum et aI, 1999; MacKie, 1999;
Richard et aI, 1999). Many of the clinicians that treat BCe
and SCC in their practices have little formal training in der-
matology (only 60% of skin cancer treatments are provided
by dermatologists) (Joseph et aI, .2001). In our study, al,most
half of the participants with more than 1 y delay were first
evaluated by a dermatologist.
On the basis of these results, we suggest that for KC,
delay after presentation to a health-care provider may be
more important than delay before initially presenting for
care. This should be evaluated in other settings and loca-
tions. Further study to investigate mediating variables in
health system delay in the diagnosis and treatment of KC is
also necessary. This inquiry should include issues of mis-
diagnosis, inadequate follow-up efforts, inadequate initial
treatment, interim events during the course of medical care,
and cost-effectiveness of available therapeutic options. KC
causes substantial morbidity, and optimal management of
this public health problem requires both primary prevention
and efficient medical management.
Methods
Subjects were selected from all cases of KC treated with MMS at
an academic dermatological surgery practice between September
12, 2000 and September 12, 2001 (n = 1123 surgical cases). These
MMS cases represented 892 different individuals. Of the surgical
patients who had more than one procedure, the s~rgical case with
the largest final defect size was selected. Im.munologically com-
promised patients were excluded. There were 20 surgical cases for
which it was not possible to calculate final defect size and 12
surgical cases in which the diagnoses were not KC; all of which
were excluded. Hence, 860 unique MMS patients were eligible for
inclusion. Cases were then stratified by size of defect into quartiles.
A random sample of 100 cases was selected using computer-
generated random numbers (Microsoft Foxpro Versio~2.6,
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assessment of three of the subcomponents of the scale: bodily
pre-occupation (scale: 0-3), disease phobia (scale: 0-4), and hy-
pochondriasis (scale: 0-3). A summary variable was also created
that utilized five-point Likert responses to a series of questions on
excuses for not seeking care (e.g. hoping spot would clear on its
own). Attitudinal Likert variables assessing confidence in detecting
skin cancer, being too busy to seek medical care, ease of obtaining .
an appointment, faith in health care, cost of health care as a prob-
lem, and tendency to wait and hope problems will go away on their
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Figure 1
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Re?mond, Washington) from each quartile except the largest, from
whIch 200 cases were selected. (Patients with large defect size
were over-sampled because factors contributing to those with
more morbidity were of special interest, and we wished to ensure
statistical stability for analysis related to these large lesions.) Ap-
proximate quartile parameters were: < 1,1-2,2-4 cm2 , and great-
er than 4 cm2 (maximum size:'43 cm2). Eighty percent of each
quartile (n = 400) were chosen for interview because of resource
constraints.
Of these 400 subjects, 28 individuals could not be reached for
interview. An additional subgroup was ineligible to participate be-
cause of communication barriers, including not speaking English
(n = 32), other communication issues (e.g. hearing loss, dementia)
(n = 43), or death (n = 5). Of those remaining, 71 people (24%) re-
fused participation, and two completed only partial interviews.
Hence, after giving verbal consent, 219 people completed the tel-
ephone interview.
Surgical records were used to obtain information recorded at
time of MMS. The remaining variables were obtained through
computer-assisted telephone interviews, which were conducted '
between January 2, 2002 and October 2, 2002 and were approx-
imately 25 min in duration. .
Analysis utilized SAS System software, release 8.2, Enterprise
Guide Version 2.0 (SAS Institute, Cary, North Carolina). After
weighting the quartiles 1, 2, and 3 by a factor of 2 to reflect the
sampling method, size was transformed, using a log transforma-
tion, to graphically approximate a normal distribution.
Weighted linear regression was used to model the tran~formed­
dependent variable, log final size of surgical defect. Residuals were
checked using a Q-Q plot, and co-linearity was assessed using
variance inflation factors. The following variables were evaluated
using linear regression to establish the base model in the overall
sample of 500 subjects: age, gender, histologic subtype, anatomic
location, an age x gender interaction, and age-squared. Control-
ling for the base model variables, remaining variables were then
entered into the model individually. In separate analys~s, predic-
tors of delay were examined using logistic regression and I X2 test
(or Fisher's exact test, if appropriate).
Twenty different anatomic locations were defined a priori using
information recorded at the time of surgery. These anatomic areas
were obtained from the chart (Table I). Comparison was to the
location of the nose, the most common location of lesions. BCC
and SCC histologic subtypes were obtained from records. Be-
cause of referral sources, 33% of charts did not have pathology
reports with information on histologic subtype (32% of the inter-
viewed and 34% of non-interviewed subjects). Review' of the
medical charts of the interviewed participants reduced the number
of missing subtypes to 20%.
Four time intervals, considered potential sources of treatment
delay, were evaluated (Fig 1). These intervals were measured and
analyzed in days (continuous variable), then by the number of the
quintile of delay (ordinal variable), and finally with indicator varia-
bles to represent each of the individual quintiles (dummy variables;
the first quintile was the comparison) to examine any possible
gradient. Quintile intervals for delay from initial evaluation approx-
imated < 1, 1-3, 3-6, 6 mo to 1 y, and greater than 1 y between
reference date and date of MMS. All dates were available for 196
patients (89.5%). '
We hypothesized that demographic, socio-economic, health-
care resources, and psychosocial variables may be related to de-
lay, and hence defect size. Other factors analyzed were: marital
~tatus, living alone, education level completed (a 1-6 scale, rang-
Ing from less than ninth grade to graduate school degree), smoking
status, provider skin examination (both as dichotomous variable
representing having had examination that year and as a variable
with a 1-5 scale, ranging from never to monthly examination), SSE
(both as dichotomous variable representing having had examina-
tion that year and as a variable with a 1-5 scale, ranging from never
to monthly exam), preVious history of skin cancer, family history of
skin cancer, personal history of any cancer other than skin cancer,
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